Thus, inhibition of SMARCA2 in the background of SMARCA4 genetic inactivation leads to synthetic lethality as the cell loses the ability to complete an essential function necessary for survival, as is the case with ENO1/ENO2 in GBM. The gene discussed is ENO1; the disease is glioblastoma.